FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971369673> ?p ?o ?g. }

• W1971369673 endingPage "1416" @default.
• W1971369673 startingPage "1416" @default.
• W1971369673 abstract "Abstract Many tumor cells utilize altered metabolic pathways to meet the bioenergetic and biosynthetic demands of rapid and sustained growth. One of the key nutrients that fuels tumor growth is the amino acid glutamine. It has long been recognized that the growth and survival of many tumor cell lines in vitro is dependent on extracellular glutamine. A critical step in the utilization of glutamine is its conversion to glutamate by the mitochondrial enzyme glutaminase. Glutamate and glutamate-derived metabolites in turn support a number of crucial cellular pathways including the citric acid cycle, redox balance and amino acid synthesis. CB-839 is a novel and selective inhibitor of glutaminase that has antitumor activity in preclinical models of triple negative breast cancer (TNBC), a tumor type that is particularly dependent on glutamine. Across a panel of breast cancer cell lines, the activity of CB-839 correlates with high expression of glutaminase, specifically the GAC splice variant but not the KGA splice variant, and low expression of glutamine synthetase (GLUL), an enzyme that converts glutamate to glutamine. This expression pattern is found in primary TNBC tumors suggesting a reliance on exogenous glutamine and glutaminase activity in vivo. To determine if other tumor types have a similar expression pattern, we undertook a systematic evaluation of GAC, KGA and GLUL expression across a diverse set of primary tumors using a normalized microarray dataset allowing comparison across a range of tumor and normal tissue samples. Elevated GAC and decreased GLUL expression relative to other tumor types or corresponding normal tissue was identified in a number of tumor types including non-small cell lung cancer, multiple myeloma, and non-Hodgkin's lymphoma. To explore whether this expression pattern predicts a reliance on glutamine and glutaminase, we tested the glutamine dependence and the activity of CB-839 on a panel of 72 cell lines representing 5 tumor types indicated by the primary tumor expression analysis. Across this cell line panel, the majority were dependent on glutamine showing either cell death, growth arrest or slowed growth after glutamine withdrawal. Similarly, CB-839 had antiproliferative activity in the majority of cell lines with IC50s in the range of 10-300 nM. Importantly, there was a strong correlation between glutamine dependence and response to 1 µM CB-839 as measured by relative cell growth or death (correlation coefficient 0.72, p&lt;0.0001), suggesting that the glutamine requirement for tumor cell growth or survival is mediated by glutaminase and that this phenotype is consistent across numerous tumor types. These data suggest that CB-839 may have therapeutic activity in a range of tumor types that are glutamine dependent and motivate the clinical evaluation of this compound targeting a novel tumor survival pathway. Citation Format: Francesco Parlati, Susan D. Demo, Matthew I. Gross, Julie R. Janes, Evan R. Lewis, Andy L. MacKinnon, Mirna L.M. Rodriguez, Peter J. Shwonek, Taotao Wang, Jinfu Yang, Dong Zhang, Frances Zhao, Mark K. Bennett. CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1416. doi:10.1158/1538-7445.AM2014-1416" @default.
• W1971369673 created "2016-06-24" @default.
• W1971369673 creator A5005410943 @default.
• W1971369673 creator A5013456495 @default.
• W1971369673 creator A5013905850 @default.
• W1971369673 creator A5028427893 @default.
• W1971369673 creator A5030446424 @default.
• W1971369673 creator A5032572799 @default.
• W1971369673 creator A5043061822 @default.
• W1971369673 creator A5055304416 @default.
• W1971369673 creator A5066110295 @default.
• W1971369673 creator A5068713194 @default.
• W1971369673 creator A5079083850 @default.
• W1971369673 creator A5081005386 @default.
• W1971369673 creator A5083336879 @default.
• W1971369673 date "2014-10-01" @default.
• W1971369673 modified "2023-09-27" @default.
• W1971369673 title "Abstract 1416: CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies" @default.
• W1971369673 doi "https://doi.org/10.1158/1538-7445.am2014-1416" @default.
• W1971369673 hasPublicationYear "2014" @default.
• W1971369673 type Work @default.
• W1971369673 sameAs 1971369673 @default.
• W1971369673 citedByCount "9" @default.
• W1971369673 countsByYear W19713696732015 @default.
• W1971369673 countsByYear W19713696732018 @default.
• W1971369673 countsByYear W19713696732020 @default.
• W1971369673 countsByYear W19713696732021 @default.
• W1971369673 countsByYear W19713696732022 @default.
• W1971369673 crossrefType "journal-article" @default.
• W1971369673 hasAuthorship W1971369673A5005410943 @default.
• W1971369673 hasAuthorship W1971369673A5013456495 @default.
• W1971369673 hasAuthorship W1971369673A5013905850 @default.
• W1971369673 hasAuthorship W1971369673A5028427893 @default.
• W1971369673 hasAuthorship W1971369673A5030446424 @default.
• W1971369673 hasAuthorship W1971369673A5032572799 @default.
• W1971369673 hasAuthorship W1971369673A5043061822 @default.
• W1971369673 hasAuthorship W1971369673A5055304416 @default.
• W1971369673 hasAuthorship W1971369673A5066110295 @default.
• W1971369673 hasAuthorship W1971369673A5068713194 @default.
• W1971369673 hasAuthorship W1971369673A5079083850 @default.
• W1971369673 hasAuthorship W1971369673A5081005386 @default.
• W1971369673 hasAuthorship W1971369673A5083336879 @default.
• W1971369673 hasConcept C109549099 @default.
• W1971369673 hasConcept C170493617 @default.
• W1971369673 hasConcept C181199279 @default.
• W1971369673 hasConcept C185592680 @default.
• W1971369673 hasConcept C2777202666 @default.
• W1971369673 hasConcept C2778160063 @default.
• W1971369673 hasConcept C2779289688 @default.
• W1971369673 hasConcept C2779349466 @default.
• W1971369673 hasConcept C502942594 @default.
• W1971369673 hasConcept C515207424 @default.
• W1971369673 hasConcept C54355233 @default.
• W1971369673 hasConcept C55493867 @default.
• W1971369673 hasConcept C61174792 @default.
• W1971369673 hasConcept C81885089 @default.
• W1971369673 hasConcept C86803240 @default.
• W1971369673 hasConceptScore W1971369673C109549099 @default.
• W1971369673 hasConceptScore W1971369673C170493617 @default.
• W1971369673 hasConceptScore W1971369673C181199279 @default.
• W1971369673 hasConceptScore W1971369673C185592680 @default.
• W1971369673 hasConceptScore W1971369673C2777202666 @default.
• W1971369673 hasConceptScore W1971369673C2778160063 @default.
• W1971369673 hasConceptScore W1971369673C2779289688 @default.
• W1971369673 hasConceptScore W1971369673C2779349466 @default.
• W1971369673 hasConceptScore W1971369673C502942594 @default.
• W1971369673 hasConceptScore W1971369673C515207424 @default.
• W1971369673 hasConceptScore W1971369673C54355233 @default.
• W1971369673 hasConceptScore W1971369673C55493867 @default.
• W1971369673 hasConceptScore W1971369673C61174792 @default.
• W1971369673 hasConceptScore W1971369673C81885089 @default.
• W1971369673 hasConceptScore W1971369673C86803240 @default.
• W1971369673 hasIssue "19_Supplement" @default.
• W1971369673 hasLocation W19713696731 @default.
• W1971369673 hasOpenAccess W1971369673 @default.
• W1971369673 hasPrimaryLocation W19713696731 @default.
• W1971369673 hasRelatedWork W1864249421 @default.
• W1971369673 hasRelatedWork W2005138612 @default.
• W1971369673 hasRelatedWork W2011036342 @default.
• W1971369673 hasRelatedWork W2038954233 @default.
• W1971369673 hasRelatedWork W2050094354 @default.
• W1971369673 hasRelatedWork W2086392715 @default.
• W1971369673 hasRelatedWork W2093173664 @default.
• W1971369673 hasRelatedWork W2954102945 @default.
• W1971369673 hasRelatedWork W2187102384 @default.
• W1971369673 hasRelatedWork W2566453024 @default.
• W1971369673 hasVolume "74" @default.
• W1971369673 isParatext "false" @default.
• W1971369673 isRetracted "false" @default.
• W1971369673 magId "1971369673" @default.
• W1971369673 workType "article" @default.